Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy

Multimodal therapy is often used in oncology to overcome dosing limitations and chemoresistance. Recently, combination immunoradiotherapy has shown great promise in a select subset of patients with colorectal cancer (CRC). Furthermore, molecularly targeted agents delivered in tandem with immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, M.R., DuRoss, A.N., Neufeld, M.J., Hahn, L., Sahay, G., Luxenhofer, R., Sun, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689338/
https://www.ncbi.nlm.nih.gov/pubmed/33294836
http://dx.doi.org/10.1016/j.mtbio.2020.100082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689338/
https://www.ncbi.nlm.nih.gov/pubmed/33294836
http://dx.doi.org/10.1016/j.mtbio.2020.100082

Ejemplares similares